Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 251-260 of 315 for Lung cancer

Edit search filters
  1. Screening for High Frequency Malignant Disease

    Rochester, MN, Eau Claire, WI, La Crosse, WI

  2. Treatment of Multifocal Lung Adenocarcinoma

    Rochester, MN

  3. A Study to Evaluate DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study

    Rochester, MN

  4. A Study to Analyze Isolation, Activation and Expansion of Mutation Reactive T-cells

    Rochester, MN

  5. Breath Condensate of Lung Cancer Patients and Healthy Controls to Measure RNA Species in Exhaled Breath Condensate

    Rochester, MN

  6. Identification of a Plasma Proteomic Signature for Lung Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

  7. A Study to Evaluate Screening Biomarkers for Lung Cancer

    Jacksonville, FL

  8. Shared Decision-Making Encounter Tool for Decisions of Adjuvant Treatment in Patients with Resected Non-Small Cell Lung Cancer

    Rochester, MN

  9. Preclinical drug testing and assay development for lung adenocarcinoma characterized by the expression of ASCL1

    Rochester, MN

  10. Alpha-1 AD Carriers and Lung Cancer Risk

    Rochester, MN

.

Mayo Clinic Footer